title: Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.
authors: Hans E
authors: HE
authors: Johnsen
authors: Corrine
authors: C
authors: Haioun
authors: Pieternella J
authors: PJ
authors: Lugtenburg
authors: Antonio
authors: A
authors: Salar
authors: Ulrich
authors: U
authors: Jaeger
authors: Ruth
authors: R
authors: Pettengell
authors: Francesca G
authors: FG
authors: Rossi
authors: Gregor
authors: G
authors: Verhoef
authors: Matthias
authors: M
authors: Schwenkglenks
authors: Kate
authors: K
authors: Bendall
authors: Ulrich
authors: U
authors: Duehrsen
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived; D018890:Chemoprevention / Q000379:methods; D003520:Cyclophosphamide; D004317:Doxorubicin; D004334:Drug Administration Schedule; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D011239:Prednisolone; D011292:Premedication / Q000379:methods; D000069283:Rituximab; D014750:Vincristine
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D016179:Granulocyte Colony-Stimulating Factor; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone